Navigation Links
ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
Date:1/25/2008

pies for vascular disorders. The Company's commercialization efforts are currently focused on its product, urokinase for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release, which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include those related to our expectation that the FDA approval of our lot release will allow the company to unlock additional value from our unlabeled urokinase inventory and that the company will benefit from cost- savings associated with prolonged shelf-life for future urokinase supplies. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include: sales of urokinase may decline and there may be insufficient demand for the product; the FDA may not approve our future requests for lot release which would result in insufficient supply of product thereby reducing sales of urokinase; we may not enter into a final agreement with Microbix for the manufacture of additional supplies of urokinase and the manufacturing process for urokinase may not be successfully transferred to Microbix; and, we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 25, 2008, and the Company undertakes no duty to update this information. A more
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
2. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
9. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
10. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
11. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... (PRWEB) November 22, 2014 Respiratory ... simulate the proper management of life-like respiratory ailments ... lung devices . Grand Rapids-based, Michigan Instruments Inc. ... donate two of the respiratory simulation units to ... each. Grand Valley and Muskegon Community College are ...
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... , Nov. 21, 2014   TRU-D SmartUVC LLC ... their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, at FIS ... from Nov. 23 to 26 at Stand 23. ... United Kingdom,s largest infection-related event of ... societies to one of the leading events of its type ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Offering ... their Sartorius Entris Balance promotion . The Sartorius ... seeking a durable, high accuracy, and easy-to-maintain balance entry ... in Germany. It was designed to help customer’s bridge ... and a balance that is very durable. Sartorius is ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2
... Using UNOsphere S and CHT , ... , Henry Lai, PhD, and Samuel G Franklin, PhD, Bio-Rad ... , , ... variety of sources have been purified , using the ...
... , Kevin McKernan, Jim Yang, Betty Woolf, Rey Sequerra, ... Agencourt Bioscience Corporation, Beverly, MA 01915, USA, ... and its relationship to drug response , and disease ... design and clinical trials. , Since the completion of ...
... , Agencourts RNAClean kit provides a simple, flexible ... acid products generated in common enzymatic , RT ... microarray , gene expression analysis experiments and is ... RNAClean eliminates the need for vacuum filtration or , ...
Cached Biology Technology:Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4SeeSNP Propietary Analysis Advantages 2SeeSNP Propietary Analysis Advantages 3SeeSNP Propietary Analysis Advantages 4SeeSNP Propietary Analysis Advantages 5SeeSNP Propietary Analysis Advantages 6RNAClean - RNA & cDNA in vitro Reaction Purification 2
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2
... published in the October 2011 issue of Experimental ... Columbia University Medical Center led by Stephen Tsang, MD, ... a mouse model for retinitis pigmentosa (RP) using novel ... disorder characterized by progressive degeneration of rod photoreceptors (which ...
... 2011 A glucosamine-like dietary supplement suppresses the damaging ... UC Irvine study. UCI,s Dr. Michael Demetriou, Ani ... is similar to but more effective than the widely ... T-cells that in MS incorrectly direct the immune system ...
... Ph.D., a Weintraub Scholar in the Basic Sciences Division ... of the National Institutes of Health Director,s Early Independence ... of 10 junior U.S. investigators to receive the honor. ... support their research over a five-year period; Olsen will ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Glucosamine-like supplement suppresses multiple sclerosis attacks 2Hutchinson Center scientist wins first NIH Director's Early Indpendence Award 2
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
Criterion staining and blotting trays are plastic trays designed for staining one or two Criterion gels or performing western blot detection. The trays have a working capacity of up to 500 ml. Suppli...
... The Biomek FX provides complete ... applications. With 96-, 384-, ... heads in either single or ... FX offers maximum speed and ...
... any standard fixed-angle microcentrifuge rotor at ... centrifuge tube filters consist of a ... tube. They filter by centrifugation for ... preparation, removal of cells from media ...
Biology Products: